First patients dosed in Phase 1 clinical trials of NEOK001 and NEOK002, bispecific ADCs targeting difficult-to-treat solid tumor cancers Initiation of the Phase 1 studies represents NEOK's transition ...
BURLINGAME, Calif., March 02, 2026--(BUSINESS WIRE)--NEOK Bio, Inc., an oncology therapeutics company focused on the development of novel antibody drug conjugates (ADCs) for improving outcomes for ...
Neok Bio has exited stealth with $75 million to take a pair of bispecific antibody-drug conjugates sourced from ABL Bio into the clinic. ABL, a Korean biotech that is partnered with companies ...
Poster sessions to highlight encouraging preclinical data for NEOK001 (ABL206), a first-in-class bispecific ADC targeting B7-H3 and ROR1-expressing solid tumors, and NEOK002 (ABL209), a bispecific ADC ...
- Backed by ABL Bio, a world leader in antibody engineering, NEOK is advancing a pipeline of differentiated bispecific antibody drug conjugates for a wide range of solid tumors - Company plans to ...
BEIJING--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel ...
Antibody-Drug Conjugate (ADC) corporations ABL Bio said on the 2nd that Neok Bio submitted an investigational new drug application (IND) to the U.S. Food and Drug Administration (FDA) on the 30th of ...
Neok Bio Inc. was formed earlier this year and is already on schedule to file an IND in a few months for its two bispecific antibody-drug conjugates (ADCs) to treat various types of tumors. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results